Meril Life Sciences Pvt. Ltd.
19
4
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
5.3%
1 terminated/withdrawn out of 19 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Comparison of Myval THV Series With Guideline-Directed Medical Therapy in Participants With Moderate Aortic Stenosis
Role: lead
Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
Role: lead
Safety and Performance of Dafodil Heart Valves in Real-World Aortic and Mitral Valve Replacement
Role: lead
Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry
Role: collaborator
OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure
Role: collaborator
MYLEAD Spanish Prospective Registry
Role: collaborator
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
Role: lead
Myval Global Study of Myval™ THV Series Implanted in Patients With Native Severe Aortic Valve Stenosis.
Role: lead
Scoring-Balloon Angioplasty and Sirolimus-Eluting Balloon Angioplasty for the Treatment of Diffuse, Small Vessel Coronary Artery Disease (SCA-DEB Study)
Role: collaborator
Freedom® Total Knee System for Treatment of Osteoarthritis, Rheumatoid Arthritis or Post-traumatic Arthritis
Role: lead
A Prospective, Single-arm, Multi-centre, Observational, Real World Registry
Role: lead
THREE-row Circular STAPLER in Low Anterior Resection for Rectal Cancer
Role: collaborator
Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
Role: lead
Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.
Role: lead
Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
Role: lead
BioMime Vs. Xience Randomised Control Clinical Study
Role: lead
An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.
Role: lead
Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions
Role: lead
Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent
Role: collaborator
All 19 trials loaded